Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.44), in-line with the analyst estimate of ($0.44). Revenue for the quarter came in at $1.86 million versus the consensus estimate of $1.58 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.